EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Hyperkalemia Is an Underestimated Risk Factor in COPD

Jukka Mäenpää, Isobel Anderson, Caroline A Owen, Ulrika Emerath, Rod Hughes, Stefan R Sultana, Marita Olsson

International Journal of Chronic Obstructive Pulmonary Disease · 2025

DOI: 10.2147/copd.s490620 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025. Verfasst von Jukka Mäenpää und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chief Medical Office, Research & Development, Patient Safety Biopharma, AstraZeneca, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Hyperkalemia, Potassium, Lung. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hyperkalemia increases mortality in various patient populations. The risk of hyperkalemia in COPD patients is poorly recognized. Hyperkalemia may increase cardiovascular mortality during and soon after COPD exacerbations. Patients and Methods: A cohort based on two clinical trials comprising 7968 patients with moderate-to-very severe COPD was analysed retrospectively for associations between hyperkalemia and common comorbidities such as chronic kidney disease, diabetes mellitus (DM), or renin-angiotensin-aldosterone system inhibitor use.

Results

Overall, 6.4% of 7968 patients had hyperkalemia (5.3% Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2, 6.8% GOLD 3, and 8.0% GOLD 4). COPD severity was associated with significantly higher hyperkalemia risk in GOLD 3 (odds ratio [OR]=1.28, 95% CI 1.04-1.58) and GOLD 4 (OR=1.64, 95% CI 1.19-2.22) versus GOLD 2 patients. Hyperkalemia cases increased with decreasing renal function. Patients with moderate-to-severe renal impairment had >2-fold increased hyperkalemia risk versus those with normal renal function (OR=2.29, 95% CI 1.71-3.04). DM was associated with increased hyperkalemia risk (OR=1.28, 95% CI 1.02-1.59). Angiotensin-converting-enzyme inhibitor (ACEi) use increased hyperkalemia risk (OR=1.25, 95% CI 1.02-1.53). Unexpectedly, the association between hyperkalemia and renin-angiotensin-aldosterone system inhibitor use was statistically significant only in the normal renal function group (OR=1.63, 95% CI 1.13-2.34).

Conclusion

Hyperkalemia risk is higher in severe and very severe COPD patients than patients with moderate COPD. Hyperkalemia was also associated with decreasing kidney function, DM, and ACEi use. Serum potassium levels should be monitored regularly in patients with COPD, particularly those with GOLD-3 and 4.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveHyperkalemiaPotassiumLungHumansRisk FactorsMaleAgedRetrospective StudiesFemaleMiddle AgedSeverity of Illness IndexOdds RatioRisk AssessmentComorbidityBiomarkersAngiotensin-Converting Enzyme InhibitorsLogistic ModelsChi-Square DistributionKidneyRenal Insufficiency, Chronic

Stichwörter der Autor:innen

angiotensin-converting-enzyme inhibitorcardiac arrhythmiaschronic kidney diseaserenin-angiotensin-aldosterone system inhibitorsserum bicarbonates

Substanzen

PotassiumBiomarkersAngiotensin-Converting Enzyme Inhibitors

Autor:innen und Institutionen

  • Chief Medical Office, Research & Development, Patient Safety Biopharma, AstraZeneca, Gothenburg, Sweden.
  • Patient Safety Operations, Technology & Analytics, Global Patient Safety, AstraZeneca, Macclesfield, UK.
  • BioPharmaceuticals, Early Clinical Development, AstraZeneca, Gaithersburg, MD, USA.
  • BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
  • Cardiovascular Safety Center of Excellence and Safety Knowledge Groups, Global Patient Safety, AstraZeneca, Cambridge, UK.
  • BioPharma Late-Stage Development Respiratory & Immunology, Biometrics and Statistical Innovation, AstraZeneca, Gothenburg, Sweden.

Zitieren

APA

Mäenpää, J., Anderson, I., Owen, C. A., Emerath, U., Hughes, R., Sultana, S. R., & Olsson, M. (2025). Hyperkalemia Is an Underestimated Risk Factor in COPD. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s490620

Vancouver

Mäenpää J, Anderson I, Owen CA, Emerath U, Hughes R, Sultana SR, et al. Hyperkalemia Is an Underestimated Risk Factor in COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s490620

BibTeX
@article{Menp2025,
  author = {Mäenpää, Jukka and Anderson, Isobel and Owen, Caroline A and Emerath, Ulrika and Hughes, Rod and Sultana, Stefan R and Olsson, Marita},
  title = {Hyperkalemia Is an Underestimated Risk Factor in COPD},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2025},
  doi = {10.2147/copd.s490620}
}
Kostenlos starten →